Profile
David Dornan is Chief Scientific Officer at Whitehawk Therapeutics, Inc. since 2025.
Former roles include Chief Scientific Officer at Elevation Oncology, Inc. from 2022 to 2025, Senior Vice President-Research & Manufacturing at Bolt Biotherapeutics, Inc. from 2019 to 2022, and Director & Head-Oncology Research at Gilead Sciences, Inc. from 2012 to 2017.
Education includes a doctorate from the University Of Dundee and an undergraduate degree from the University of Strathclyde.
David Dornan active positions
| Companies | Position | Start |
|---|---|---|
| WHITEHAWK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2025-02-17 |
Former positions of David Dornan
| Companies | Position | End |
|---|---|---|
| ELEN ONCO | Chief Tech/Sci/R&D Officer | 2025-02-16 |
| BOLT BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-03-10 |
| GILEAD SCIENCES, INC. | Director/Board Member | 2017-10-31 |
Training of David Dornan
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
University Of Dundee
University Of Dundee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Elevation Oncology, Inc.
Elevation Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops elevating precision medicines for cancer treatment | Health Technology |
Aadi Bioscience, Inc.
Aadi Bioscience, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
- Stock Market
- Insiders
- David Dornan
















